Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis
BackgroundHLX02 is the first China-manufactured trastuzumab biosimilar. Few data are currently available about HLX02 in clinical practice. This study was designed to evaluate the real-world safety and efficacy of HLX02 in patients with HER2-positive metastatic breast cancer (MBC), as well as assesse...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2025-08-01
|
| Serie: | Frontiers in Oncology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1622854/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|